Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov) - Oct 3, 2026 - P1/2 | N=56 | Active, not recruiting | Sponsor: University of Washington | Phase classification: P1 ➔ P1/2
Phase classification • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • BCL2 • BCL6 • CD20
|